Results 31 to 40 of about 106,555 (305)
A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs
Molecular & Cellular Oncology, 2021 While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder +2 more
doaj +1 more source
Feline primary erythrocytosis: a multicentre case series of 18 cats [PDF]
, 2018 A retrospective multicentre case series of feline primary erythrocytosis (PE) was evaluated. The aim was to gain better understanding of disease presentation and progression to guide management and prognostication. Case records were assessed for evidence
Balazs Szladovits +7 more
core +2 more sources
Britannin suppresses MCF-7 breast cancer cell growth by inducing apoptosis and inhibiting autophagy [PDF]
Avicenna Journal of PhytomedicineObjective: Breast cancer is the main reason for cancer-related death in women. Britannin is a sesquiterpene lactone compound derived from Inula aucheriana with anti-tumor properties. We aimed to explore the impacts of britannin on apoptosis and autophagy
Sadegh Rajabi +3 more
doaj +1 more source
Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma [PDF]
, 2015 The prevalence of global obesity is increasing. Obesity is associated with general cancer-related morbidity and mortality and is a known risk factor for development of specific cancers.
Alfraidi, Albandri +5 more
core +2 more sources
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
Oncotarget, 2011 Most BCR-ABL1-negative myeloproliferative neoplasms (MPN) carry an activating JAK2 mutation. Approximately 96% of patients with polycythemia vera (PV) harbors the V617F mutation in JAK2 exon 14, whereas the minority of JAK2 (V617F)-negative subjects shows several mutations in exon 12. Other mutation events as MPL, TET2, LNK, EZH2 have been described in
PASSAMONTI, FRANCESCO +3 more
openaire +4 more sources
JAK2, STAT3 Gene Polymorphisms in Turkish Patients with Behçet’s Disease
Gazi Medical JournalObjective: Behçet’s disease (BD) is a chronic, multisystemic inflammatory disorder with an unknown etiology. T cells are crucial in the pathogenesis of BD.
Darya Farhoomand Aksoy +3 more
doaj +1 more source
The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]
, 2017 Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core +1 more source
PLoS ONE, 2022 JAK2 is cytokine-activated non-receptor tyrosine kinase. Although JAK2 is mainly localized at the plasma membrane, it is also present on the centrosome. In this study, we demonstrated that JAK2 localization to the centrosome depends on the SH2 domain and
Aashirwad Shahi +3 more
doaj +1 more source
Erythematous Macular Eruption in an Older Woman [PDF]
, 2019 A white woman in her 70s with advanced Alzheimer disease was referred to the hematology clinic for evaluation of a high hemoglobin level (169 g/L; normal range, 120-160 g/L) and red blood cell count (5.67 × 1012/L; normal range, 3.8-4.8 × 1012/L) as well
Kernohan, Neil +2 more
core +2 more sources
Enu mutagenesis identifies a novel platelet phenotype in a loss-of-function Jak2 allele. [PDF]
PLoS ONE, 2013 Utilizing ENU mutagenesis, we identified a mutant mouse with elevated platelets. Genetic mapping localized the mutation to an interval on chromosome 19 that encodes the Jak2 tyrosine kinase.
Nicole M Anderson +16 more
doaj +1 more source